ObsEva Announces Appointment of Annette Clancy as Chair of the Board of Directors
May 19 2022 - 7:05AM
GENEVA, Switzerland
May 19,
2022 – ObsEva SA (NASDAQ: OBSV; SIX:
OBSN), a biopharmaceutical company developing and
commercializing novel therapies for women’s health, today announced
the appointment of Annette Clancy as Chair of the Board of
Directors at the Company’s Annual General Meeting on May 18, 2022.
Ms. Clancy has served as a member of ObsEva’s Board of Directors
since 2013 and was previously Chair from November 2013 to December
2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to
step down from the role of Chair and retire from the Board of
Directors, effective following the conclusion of the Annual General
Meeting.
“We could not be more pleased, or fortunate, to
have Annette return to the Chair position as we prepare for our
first approvals and transition to a commercial stage company,” said
Brian O’Callaghan, CEO of ObsEva. “Annette’s contributions to
ObsEva are undisputed and her distinguished career spanning
research and development, commercialization, and business
development constitute the ideal skill set to position ObsEva for
success in this next stage of growth. I would also like to
sincerely thank Frank for his years of Board contribution. The
tremendous progress across the pipeline, which positions ObsEva for
upcoming milestones, is a testament to Frank’s Board leadership. We
wish him success in his future pursuits.”
Ms. Clancy has over 30 years’ experience in the
pharmaceutical industry, including fifteen years in business
development at GlaxoSmithKline (GSK) where she was most recently
Head of Transactions and Alliance Management, responsible for
innovative deals ranging from early drug discovery partnerships to
global commercial alliances, and mergers and acquisitions. Since
her retirement from GSK in 2008, Ms. Clancy has advised venture
capital health groups in the United States and Europe, namely as an
Operational Investor for Jeito Capital and previously a Senior
Advisor to Frazier Healthcare Ventures. Ms. Clancy has extensive
Board experience and in addition to her role with ObsEva, she is
Chair of the privately held French company, Enyo SA, and a
non-Executive Director of the Swedish public company, Sobi. Prior
to Ms. Clancy’s time in business development, she held a number of
positions in clinical research, research and development project
management, and commercialization. Ms. Clancy holds a BSc (Hons)
Pharmacology from Bath University (UK) and a series of American
Management Association diplomas (finance/marketing).
Ms. Clancy commented, “I’m honored to be
reprising the role of Chair at ObsEva at this pivotal time and
building on the momentum created by Frank and the executive team as
ObsEva prepares for commercial launch. My dedication to ObsEva and
conviction in its prospects is long-standing, and I am excited to
be presiding over this potentially transformational period as we
pursue our first approvals and seek to change the treatment
paradigm for women with uterine fibroids and other underserved
conditions.”
Dr. Verwiel commented, “It is a privilege to
have been part of the exceptional team at ObsEva over the past six
years, and I take great pride in all that we have accomplished
together. I look forward to following ObsEva’s continued
achievement as the company nears prospective approval of linzagolix
and pursues its vision of delivering life-changing therapies to
address the most challenging unmet needs facing women.”
About ObsEva
ObsEva is a biopharmaceutical company developing
and commercializing novel therapies to improve women’s health.
Through strategic in-licensing and disciplined drug development,
ObsEva has established a late-stage clinical pipeline with
development programs focused on new therapies for the treatment of
uterine fibroids, endometriosis, and preterm labor. ObsEva is
listed on the Nasdaq Global Select Market and is traded under the
ticker symbol “OBSV” and on the SIX Swiss Exchange where it is
traded under the ticker symbol “OBSN”. For more information, please
visit www.ObsEva.com.
Cautionary Note Regarding
Forward-Looking Statements
Any statements contained in this press release
that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. These statements may be
identified by words such as “anticipate”, “believe”, “continue”,
“could”, “estimate”, “expect”, “intend”, “may”, “might”, “ongoing”,
“objective”, “plan”, “potential”, “predict”, “should”, “will”,
“would”, or the negative of these and similar expressions, and are
based on ObsEva’s current beliefs and expectations. These
forward-looking statements include expectations regarding the
potential approval of linzagolix by regulatory authorities,
including the European Commission and the U.S. Food and Drug
Administration (FDA), and the timing of such approval and
subsequent transition of ObsEva to a commercial-stage company, the
timing or results of interactions with regulatory authorities,
clinical development of ObsEva’s product candidates, including the
timing, advancement of, and potential therapeutic benefits of such
product candidates, including linzagolix, the potential for
linzagolix and other product candidates to be commercially
competitive, the success of the Company’s partnerships with third
parties, expectations regarding regulatory and development
milestones and ObsEva’s ability to obtain and maintain regulatory
approvals for its product candidates. These statements involve
risks and uncertainties that could cause actual results to differ
materially from those reflected in such statements. Risks and
uncertainties that may cause actual results to differ materially
include uncertainties inherent in the conduct of clinical trials
and clinical development, including the risk that the results of
earlier clinical trials may not be predictive of the results of
later stage clinical trials, related interactions with regulators,
including interactions with the European Medicines Agency during
the marketing authorization application process and with the FDA
during the New Drug Application process for linzagolix, ObsEva’s
reliance on third parties over which it may not always have full
control, and the capabilities of such third parties, the impact of
the ongoing novel coronavirus outbreak and other geopolitical
events, and other risks and uncertainties that are described in the
Risk Factors section of ObsEva’s Annual Report on Form 20-F for the
year ended December 31, 2021 filed with Securities and Exchange
Commission (SEC) on March 10, 2022, in the Report on Form 6-K filed
with the SEC on May 17, 2022 and other filings ObsEva makes with
the SEC. These documents are available on the Investors page of
ObsEva’s website at www.ObsEva.com. Any forward-looking statements
speak only as of the date of this press release and are based on
information available to ObsEva as of the date of this release,
and, except as required by law, ObsEva assumes no obligation to,
and does not intend to, update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
For further information, please
contact:
CEO Office contactShauna
Dillonshauna.dillon@obseva.ch+41 22 552 1550
Investor ContactKatja
BührerKatja.buhrer@obseva.com
+1 (917) 969-3438
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Mar 2024 to Apr 2024
ObsEva (NASDAQ:OBSV)
Historical Stock Chart
From Apr 2023 to Apr 2024